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Abstract
Background/Aims—Little is known about beliefs, understanding and perceptions of biobanking 
among patients with inflammatory bowel diseases (IBD). We aimed to further understand 
perceptions of biobanking in the IBD community.
Methods—Subjects were recruited to participate in a 1:1 telephone interview on their 
perceptions of the risks and benefits of contributing specimens for research. These interviews 
informed a survey instrument evaluating perceptions of biobanking within CCFA Partners cohort. 
We used descriptive statistics to summarize participant responses, and bivariate statistics to 
compare willingness to participate in biobanking by disease and demographic factors.
Results—A total of 26 interviews were conducted. Various themes emerged from the interviews 
and aided in the development of the survey instrument. Concerns focused upon storage, loss of 
confidentiality, outside uses and life insurance discrimination. A total of 1007 individuals 
completed the survey. In all, 397 (39.4%) reported they would definitely donate samples, 568 
(56.4%) would probably donate, 36 (3.6%) probably not, and 6 (0.6%) would definitely not 
donate. No significant differences in willingness to donate samples were seen for Crohn’s disease 
(CD) versus ulcerative colitis (UC) (p=0.25) or for remission versus active disease (p=0.14). For 
sample-type preference, 956 (89.6%) would donate blood, 997 (93.5 %) saliva and 822 (77.1%) 
stool.
Conclusions—Large majorities of patients with IBD demonstrated a willingness to donate 
specimens for biobanking, albeit with concerns. Addressing these concerns will enhance 
participation and engagement and create greater alignment between the desires of research 
participants and the governance structure and operating policies of biobanks.
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Introduction
Biobanks are systematic collections of samples that include human body substances (e.g. 
organs, tissue, blood) and DNA as a carrier of genetic information. Data that include 
information on the donor (demographic data, disease type) are also stored, either with the 
samples or separately.1,2 Biobanks are created with the belief that the use of human 
biospecimens in research will lead to scientific discoveries that will ultimately benefit 
society. Public surveys and focus groups demonstrate strong support for medical research,3 
yet little is known about the beliefs, understanding and perceptions of biobanking among 
patients with certain chronic disease states, including inflammatory bowel diseases (IBD).
IBD, including both Crohn’s disease (CD) and ulcerative colitis (UC), are chronic 
inflammatory disorders of the gastrointestinal tract of unknown etiology. These disorders are 
relatively rare, although increasing over time.4 Both CD and UC are thought to arise through 
a combination of factors, including genetic susceptibility, environmental exposures, 
alterations in the innate and adaptive immune system, and changes in the gut microbiota.5,6 
Researching the genetic and microbial factors involved in IBD pathogenesis (etiology and 
natural history) requires samples donated by affected patients. Such research is currently a 
high priority in IBD, creating the need for a national biobank containing samples of serum, 
saliva and stool for genetic and microbial analyses.7 The research community therefore 
needs to understand patient perceptions on biobanking. This understanding can be used to 
establish features of a biobank that are reflective of the desires and needs of IBD patients. 
This in turn may improve recruitment efforts, facilitate greater participant understanding 
during the consent process, enhance IBD patients’ engagement and experience participating 
in the biobank, and ultimately create greater alignment between patient preferences and 
biobank governance and operating policies.
We therefore sought to learn more about perceptions of biobanking in the IBD community 
through 1) a series of one-on-one interviews designed to understand attitudes related to 
biobanking among members of the CCFA Partners cohort, an Internet based cohort focusing 
upon patient reported outcomes in IBD8 and 2) a cross-sectional survey of participants in 
CCFA Partners to determine patient preferences and concerns about participation in a 
hypothetical IBD biobank. We further aimed to determine whether these preferences 
differed by demographic and disease-based characteristics.
Methods
The source of participants was the CCFA Partners Internet-cohort. The details of this cohort 
are described elsewhere.8 Briefly, this cohort was launched in 2011 with participants 
recruited via the Crohn’s and Colitis Foundation of America (CCFA) email lists, 
membership files, website, social media outreach, promotion at educational and fundraising 
efforts, and through physicians’ offices. To date, over 13,000 individuals have enrolled in 
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CCFA Partners. Participants are followed every 6 months with detailed surveys on disease 
factors and patient reported outcomes. Data from this cohort have been used to investigate 
the role of various factors in IBD exacerbation.9,10
Participants in CCFA Partners were invited to participate in a one-on-one telephone 
interview with one of three trained qualitative researchers. Recruitment was continued until 
the data from the interviews became consistent without the introduction of new themes or 
concerns. The interview included questions on their perceptions of the risks and benefits of 
contributing specimens for research, as well as various ethical and legal considerations of 
biobanking. Using standard interviewing techniques, including open-ended questions, 
responses were recorded and transcribed. Interviews averaged 35 minutes. The results of 
these interviews, along with co-authors’ prior experiences conducting studies on perceptions 
of biobanking,11 informed the development of a cross-sectional instrument to evaluate the 
cohort’s attitudes about joining a hypothetical CCFA Partners’ biobank. The survey was 
offered to CCFA Partners participants from August 2013 until October 2013 until a goal of 
1000 responses were obtained.
Statistical Analysis
Interviews
All interviews were transcribed verbatim. Following classical qualitative methods,11 at least 
two members of our research team closely read each transcript and identified themes and 
patterns in responses across transcripts.
Survey
We summarized participant responses using descriptive statistics and compared willingness 
to participate in biobanking by disease type, gender, age, and severity of disease, and other 
factors using appropriate bivariate statistics.
For all analyses, a p value of 0.05 was considered statistically significant. Stata version 12.0 
(College Station, TX) was used for all analyses. The institutional review board at the 
University of North Carolina at Chapel Hill approved the study protocol.
Results
Interviews
A total of 26 interviews were conducted with CCFA Partners cohort members. Various 
themes emerged from the interviews, including concerns about the personal burden of 
donating samples; unauthorized access and/or loss of confidentiality; use of samples for 
purposes outside of IBD research; and life insurance discrimination. Perceived personal and 
societal benefits of participating in the biobank included advancing IBD research, leading to 
a cure; altruistic feelings of helping others or family members with IBD; and hope that they 
might personally benefit. These themes aided in the development of a survey instrument to 
assess perceptions of biobanking. Examples of comments of participants with IBD on their 
concerns about biobank participation are seen in figure 1. Example comments of participants 
with IBD on the potential benefits of biobanking are shown in figure 2.
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The survey was designed in sections relevant to different aspects of biobanking. These 
sections included: willingness to participate, preferences for sample use, sample types, the 
process of giving samples, structure and role of an oversight committee in biobank research, 
withdrawing from the biobank, biobank closure, biobank funding, the role of minors and 
family members, and attitudes surrounding biobanking including motivation for 
participation, future use of specimens, and expectations surrounding return of information.
A total of 1762 CCFA Partners cohort members were asked to participate in a survey of 
perceptions of biobanking, 1073 (60.9%) initiated the survey and 1007 (57.2%) completed 
the survey. The baseline characteristics of the sample who participated in the survey were 
similar to those who did not, except for educational background (supplemental table A). 
Those participating in the survey had a slightly greater percentage of college and graduate 
degrees (75.1% versus 65.5%, p=0.01).
Participants were asked whether they would agree to contribute samples to the biobank if 
they were asked. In all, 397 (39.4%) reported they would definitely donate samples, 568 
(56.4%) would probably donate, 36 (3.6%) probably not, and 6 (0.6%) would definitely not 
donate. Individuals were categorized according to these responses into donors (n=965) 
versus non-donors (n=42). Table 1 shows the characteristics of the population by donor 
status.
Preferences for samples
In regard to comfort levels for biospecimen use in certain types of research or by certain 
groups of investigators, participants overwhelmingly supported immune system, microbiota 
or genetic research specific to IBD (table 2). Participants were asked their preferences for 
donation of biological samples by type. In total, 956 (89.6%) would donate blood, 997 (93.5 
%) saliva and 822 (77.1%) stool. The majority of patients preferred collection of serum at 
the time of a clinical visit with a healthcare provider (47.1%), 34.2% had no preference and 
18.7% preferred a mobile phlebotomy service. Those willing to donate stool were offered 
varying hypothetical frequencies of stool collection. A total of 96.7% would donate one time 
in remission when feeling well, with 91.0% willing to donate one time during a disease 
flare. Markedly fewer (39.9%) were willing to donate daily over a 2 week time period, 
regardless of disease activity. A total of 58.4% would be willing to donate once a week for 8 
weeks, and 73.9% would be willing to donate once a month for 12 months.
Structure and role of an oversight committee
Participants were asked whether various community members should be a part of an 
oversight committee for an IBD biobank. These results are shown in table 3. 
Overwhelmingly, respondents believed that IBD physicians and researchers should be 
included on this panel, whereas lawyers and clergy members were not felt to be as integral a 
component to an oversight committee.
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Withdrawing from a biobank
The participants were nearly evenly split on how they would like their samples managed if 
they decided to withdraw from an IBD biobank. Participants were offered withdrawal 
options of 1) continued use of previously donated samples for research after withdrawal, but 
no requests for additional samples, 2) continued use of samples for research with destruction 
of linked personal data, or 3) destruction of samples without any further research use as 
options. A total of 34.0% would allow the samples they had previously donated to be used 
for further research, but would not want to be asked again for samples, 28% would allow 
prior samples to be used, but would want any link to their name destroyed, and just over one 
third of patients (36.9%) would want their samples destroyed upon their request. In a similar 
fashion, in regards to genetic or phenotypic information linked to the samples, 38.9% would 
allow data to be retained and used for future studies, 44.0% would want a link to their name 
removed, and only 17.6% would want this information destroyed and no longer used. An 
overwhelming percent (82.2%) felt that it would be important for the biobank to advise 
patients before they agreed to participate of what would be done with their samples and data 
should they choose to withdraw in the future.
Biobank Closure
Participants overwhelmingly (82.2%) reported that prior to participation in the IBD biobank, 
it would be important to know the plan for biological samples and genetic data in the event 
of a closure. Participants were most comfortable with giving these samples and data to other 
IBD researchers or destroying the samples and data (table 4).
Biobank funding
Approximately half of participants felt that funding source did not affect their willingness to 
participate in the biobank. Among those who were influenced by funding source, federal 
government or foundation funding made them more likely to participate, whereas 
pharmaceutical company funding provided a negative influence (table 5).
Role of minors and family members
A total of 56.6% of participants reported that they would be willing to give the names and 
contact information of their immediate family members so that they could also donate to the 
biobank. A total of 225 (22.4%) had children under the age of 18 at the time of the survey. 
These individuals were asked whether they would be willing to provide consent for sample 
donation from their minor children. Of these, 44.2% would consent for their child’s serum 
donation, 68.2% for their saliva donation and 43.8% for their stool donation.
Attitudes surrounding biobanking
Nearly all patients (98.7%) felt that contributing to the biobank would make them feel as if 
they were helping others with IBD. A similar percentage (95.1%) felt that participation in a 
research study through sample donation could potentially benefit their own health as well. 
Only a minority were afraid that their privacy would not be protected if they agreed to 
participate in the biobank (35.4%). Over half of participants feared that health or life 
insurance companies would use the research findings to discriminate against them in regards 
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to coverage (53.1%). Participants were asked about the role of incentives for participation 
and return of information from the biobank. Only 42.2% of participants reported that 
monetary compensation would increase the likelihood of their participation in the biobank. 
In comparison, a majority of participants (70.0%), reported that return of information in the 
form of newsletters reporting general results from studies would increase the likelihood of 
their participation. An even greater percent (83.7%) felt that return of research results 
specific to them as individuals (such as genetic risk factors for more aggressive disease) 
would increase their participation rate. In all, 98.3% of participants felt that this hypothetical 
biobank should be created.
Consent for biobanking
Participants were comfortable offering broad (general) consent for their samples to be used 
in all future research studies approved by the biobank’s oversight committee (89.6%). 
However, the majority of participants would want to be informed when their samples or data 
were going to be used in a research study (68.8%), while 22.9% said it would not matter and 
8.3% did not want to be informed. A total of 58.0% of participants would want the 
opportunity to say “no” to the use of their samples in specific studies. The vast majority 
were very comfortable (54.8%) or somewhat comfortable (32.0%) allowing the biobank to 
keep their samples and data indefinitely.
Discussion
Biobanks have become much more prevalent in recent years, yet there is no uniform 
guidance for those establishing biobanks on how to develop governance models that respond 
to the ethical and legal challenges that biobanks may face.12,13 Rules for biobank 
governance and informed consent vary internationally. Biobank participation rates in other 
populations and disease types have also varied. For example, in a general clinic population, 
69% reported they would participate in a biobank.14 In a group of Chinese Americans with 
hepatitis B, only 46.3% reported willingness to participate.15 Factors influencing 
participation are multifold, including ethnic, cultural and disease-specific factors. In 
contrast, studies in cancer patients have found much broader support for biobank 
participation, as long as informed consent and confidentiality could be assured.16 In our 
study, we found similar sentiments in the IBD population to those of cancer populations, 
with general support for biobanking (>90% definite or probable participation), and chief 
concerns of loss of confidentiality and the potential for discrimination in health or life 
insurance due to research findings. It is clear that participants support biobanking for 
altruistic reasons, such as improved disease understanding or treatment of IBD. 
Additionally, participation in the hypothetical IBD biobank was influenced more by return 
of information to the participants than by monetary compensation. Return of information has 
been shown to be a motivating factor for biobank participation in other populations as 
well. 17 Addressing concerns and motivating factors of participants will be important in the 
design of a national IBD biobank and could also apply to epidemiological, clinical, and 
translational studies of other chronic conditions that require the collection and storage of 
biological samples and/or genetic data.
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Biobanks must navigate the sometimes difficult tension between promoting use of their 
samples and data to facilitate research and assuring the respect and protection of 
participants.13 Many biobanks prefer to seek from potential participants general consent for 
future unlimited uses of their samples, while others choose to contact enrolled participants to 
ask them to re-consent to use a previously obtained sample.18 Those within our study 
overwhelming supported sample use in studies specific to IBD, the immune system or 
microbiota. There was less support for studies outside of IBD, and therefore a commitment 
at the time of informed consent to limit future uses of samples and genetic data to IBD 
research would be valuable. Alternately, the biobank could seek broad consent with 
assurances that people be notified of the use of their samples in research studies and be 
offered an opportunity to opt out. Ultimately, participants want choice, or tiered consent, 
with options to specify how their samples can be used in the future.
A new form of consent, dynamic consent, has recently been proposed as a modern-day 
approach to the consenting process. Central to this form of consent is a personalized, digital-
communication interface that connects researchers and participants, allowing greater 
participant involvement in decision making. This moves beyond the static, paper-based 
current form of consent which is organized around national boundaries and legal 
frameworks.19 Such as form of consent would likely meet participants’ expectations of 
retaining some control over the samples that they donate. Participants would like the ability 
to withdraw their consent and specify whether samples and data could be further used, or 
whether these samples should be destroyed. At a minimum, participants would like options 
for withdrawal and a plan for sample use or destruction after a biobank closure outlined to 
them at the time of initial consent.
There are several strengths to this study. The interviews allowed focused themes specific to 
IBD to emerge and then inform survey instrument development. The sample size of the 
survey portion of our study was large, allowing for precise estimates of participants’ 
perceptions on biobanking in the survey. Finally, the CCFA Partners cohort, although not a 
random sample of IBD patients in the U.S., is geographically diverse (it contains patients in 
all 50 U.S. states and 4 territories) and includes patients seen in multiple care settings (both 
private and academic). There are also limitations to this cross-sectional study. First, the 
participants were recruited from CCFA Partners, which is an internet-based cohort of 
predominantly individuals living within the United States (US). US perceptions may or may 
not align well with international perceptions, other cultures or ethnicities. We also do not 
have data directly from children and adolescents on their perceptions, although we do ask 
parents about sample collection from their children. Although large and diverse, the CCFA 
Partners cohort may not be generalizable to the IBD population as a whole. Disease 
characteristics within the cohort are also not uniformly validated. However, in a validation 
sample, 97% of participants’ IBD diagnoses were confirmed.20 While this methodological 
design provides a good sense about survey respondents’ attitudes toward a hypothetical 
biobank supported by CCFA Partners, an individual’s actual willingness to participate in a 
biobank may vary from his or her survey responses.21
In summary, as biobanking efforts in specific disease states, such as IBD, become more 
prevalent, incorporating patient’s preferences into the process of informed consent and other 
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policies and governance decisions are integral to ensuring patient engagement, participation, 
and ultimately sustainability of biobanks. Return of information to participants will be an 
important factor influencing participation. As the field of IBD advances and the need for 
reliable biospecimen storage and genetic and phenotypic information increases, biobanking 
will need to become more centralized. As we design a 21st century IBD biobank, 
understanding the beliefs, understanding, and perceptions of patients with IBD in regards to 
the ethical and legal aspects of biobanking will be of utmost importance.
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Concerns of participants on biobank participation
Long et al. Page 10














Participants’ perceived benefits of biobank participation
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Table 2
Comfort levels of participants for allowing use of their samples in various types of research or investigators












Genetic studies of IBD 84.6 11.6 2.0 1.8
Any genetic study 67.3 17.5 8.8 6.5
Studies of immune system 87.1 10.4 1.2 1.3
Studies of microbiota 87.5 10.0 1.5 1.0
Pharmaceutical company researcher 49.3 25.8 15.3 9.4
University researcher in the US 84.6 12.7 1.4 1.3
University researcher in other countries 55.5 20.7 12.5 11.3
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Table 3
Preference for members of an oversight committee for and inflammatory bowel disease biobank
Potential Member % reporting that they should be included in panel




People who donated samples 65.9
Lawyers 47.1
Ethicists 60.5
Members of the clergy 15.8
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Table 4













Given to other researchers conducting only IBD research 68.9 20.4 4.8 5.9
Sold to other researchers conducting only IBD research 17.6 13.1 25.9 43.4
Given to other researchers for other types of research 32.4 21.7 18.2 27.7
Sold to other researchers for other types of research 11.0 7.9 22.8 58.4













Given to other researchers conducting only IBD research 63.5 23.4 5.4 7.7
Sold to other researchers conducting only IBD research 16.9 12.6 22.2 48.4
Given to other researchers for other types of research 32.4 21.7 18.2 27.7
Sold to other researchers for other types of research 11.0 7.9 22.8 58.4
Destroyed 74.6 13.8 6.6 5.1
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Table 5
Participants’ likelihood of participation in a biobank due to funding source






Federal government (NIH*) 49.5 4.6 45.9
Pharmaceutical companies 16.5 32.0 51.5
Private foundations 46.6 4.2 49.2
*
National Institutes of Health
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